Search results
Results from the WOW.Com Content Network
A hilar cell tumor is an androgen-producing ovarian tumor that is most commonly found in older women and often leads to the development of male sex characteristics. The tumor tends to occur around the region of the ovary where the blood vessels enter the organ, known as the hilum. This type of tumor tends to be small in size and in most cases ...
Androgen-secreting tumors: Tumors in the adrenal glands or in the ovaries leading to increase levels of androgens. [19] Rapid progression and virilization symptoms. [14] Other less common hormonal causes: Acromegaly: Elevated levels of insulin-like growth factor-1. [18] Hyperthyroidism or hypothyroidism: Elevated or decreased levels of thyroid ...
The majority of Leydig cell tumors are found in males, usually at 5–10 years of age or in middle adulthood (30–60 years). Children typically present with precocious puberty. [citation needed] Due to excess testosterone secreted by the tumour, one-third of female patients present with a recent history of progressive masculinization.
Nearly one in five new cervical cancers diagnosed from 2009 to 2018 were in women 65 and older, according to a new UC Davis study.But what has experts concerned is that, according to the study ...
Now, new research finds that women who use hormone therapy after age 65 are usually fine to do just that — but the dose and timing of the treatment matter. The study, which was published in ...
An androgen-dependent condition, disease, disorder, or syndrome, is a medical condition that is, in part or full, dependent on, or is sensitive to, the presence of androgenic activity in the body. [ citation needed ]
Sertoli–Leydig cell tumour is a testosterone-secreting ovarian tumor and is a member of the sex cord-stromal tumour group [2] of ovarian and testicular cancers. The tumour occurs in early adulthood (not seen in newborn), is rare, comprising less than 1% of testicular tumours. [ 1 ]
The study, which involved 106 peri- and postmenopausal women and was presented at the Endocrine Society’s annual meeting in May, indicates women should self-monitor their vasomotor symptoms and ...